Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Perspective · 30 Mar 2022 Conference abstract · 13 Jul 2018 Activation of FcγR-dependent responses to therapeutic antibodies by Nurse Like cells requires PI3Kδ
Buparlisib) were able to inhibit ADCC in response to the CD20-targeting therapeutic antibody, obinutuzumab. Similarly, both buparlisib and idelalisib were able to inhibit AKT phosphorylation at concentrations that also
Review article · 8 Feb 2018 Competitive Treatment in Diffuse Large B-cell lymphoma (DLBCL) and the Future SOC for the First Line Therapy
Diffuse large B-cell lymphoma (DLBCL) in the most common type of
Mini review · 2014 New Therapeutic Advances in Chronic Lymphocytic Leukemia
Treatment of Chronic Lymphocytic Leukemia (CLL) is entering a new era. In
Short communication · 2 Sep 2019 Activation of FCYR-dependent responses to therapeutic antibodies by nurse like cells requires PI3KS
Buparlisib) were able to inhibit ADCC in reaction to the CD20-targeting healing antibody, obinutuzumab. Similarly, each buparlisib and idelalisib were able to inhibit AKT phosphorylation at concentrations that still
Conference abstract · 14 Nov 2018 Activation of FcγR-dependent responses to therapeutic antibodies by Nurse Like cells requires PI3Kδ
Buparlisib) were able to inhibit ADCC in response to the CD20-targeting therapeutic antibody, obinutuzumab. Similarly, both buparlisib and idelalisib were able to inhibit AKT phosphorylation at concentrations that also
Review article · 2015 Chronic Lymphocytic Leukemia: Raising Expectations in the Treatment of Elderly Patients
bendamustine, both in combination with the anti-CD20 antibodies rituximab and, more recently, obinutuzumab. Early results have been promising, and suggest the possibility of improved outcomes in this patient group

